Sino Biopharmaceutical Limited

SEHK:1177 Stok Raporu

Piyasa değeri: HK$60.1b

Sino Biopharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Sino Biopharmaceutical şirketinin toplam hissedar öz sermayesi CN¥42.1B ve toplam borcu CN¥9.5B olup, bu da borç-öz sermaye oranını 22.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥66.7B ve CN¥24.6B dir. Sino Biopharmaceutical 'in FAVÖK'ü CN¥5.9B faiz karşılama oranı -22.2 dur. Şirketin CN¥13.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

22.6%

Borç/özkaynak oranı

CN¥9.51b

Borç

Faiz karşılama oranı-22.2x
NakitCN¥13.18b
EşitlikCN¥42.12b
Toplam yükümlülüklerCN¥24.58b
Toplam varlıklarCN¥66.70b

Son finansal sağlık güncellemeleri

Recent updates

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1177 'nin kısa vadeli varlıkları ( CN¥25.2B ) kısa vadeli yükümlülüklerini ( CN¥21.9B ) aşıyor.

Uzun Vadeli Yükümlülükler: 1177 şirketinin kısa vadeli varlıkları ( CN¥25.2B ) uzun vadeli yükümlülüklerini ( CN¥2.6B ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1177 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 1177 şirketinin borç/öz sermaye oranı son 5 yılda 8.2% seviyesinden 22.6% seviyesine yükseldi.

Borç Kapsamı: 1177 'nin borcu işletme nakit akışı ( 68.1% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 1177 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.


Bilanço


Sağlıklı şirketleri keşfedin